Pulmonary-Allergy Drugs Advisory Committee

Pulmonary-Allergy Drugs Advisory Committee Committee Meeting April 17, 2013 8:00 a.m. to 5:00 p.m. Agenda : The committee will discuss the new drug application (NDA) 204275 for fluticasone furoate and vilanterol dry powder inhaler (proposed tradename BREO ELLIPTA), sponsored by GlaxoSmithKline, for the long-term maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease.